Business
Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights
PEMGARDA™ (pemivibart) net product revenue of $11.3 million reported for Q1 2025, influenced by planned transition (Jan/Feb) from a contracted to an internalized sales forcePEMGARDA revenue re-acceleration observed in Q2 2025 to dateInvivyd continues to target near-term profitability (1H 2025) with existing cash and cash equivalents, anticipated growth of net product revenue, and continued reduction of operating expensesSince Emergency Use Authorization (EUA) of PEMGARDA in March 2024, no docume
About this update from Invivyd, Inc.
[{"type":"image","alt":"Invivyd","displaySize":"","headline":null,"caption":"Invivyd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":44,"url":"https://media.zenfs.com/en/globenewswire.com/4a4d9d450de79e16fc0a485fff104ca6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MyR5b2vdhRgALtKrzLKLAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/4a4d9d450de79e16fc0a485fff104ca6","width":300,"height":44}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"PEMGARDA™ (pemivibart) net product revenue of $11.3 million reported for Q1 2025, influenced by planned transition (Jan/Feb) from a contracted to an internalized sales force","length":173,"tagName":"p"}]},{"val":[{"type":"text","content":"PEMGARDA revenue re-acceleration observed in Q2 2025 to date","length":60,"tagName":"p"}]},{"val":[{"type":"text","content":"Invivyd continues to target near-term profitability (1H 2025) with existing cash and cash equivalents, anticipated growth of net product revenue, and continued reduction of operating expenses","length":191,"tagName":"p"}]},{"val":[{"type":"text","content":"Since Emergency Use Authorization (EUA) of PEMGARDA in March 2024, no documented cases of anaphylaxis reported, across thousands of post-authorization doses","length":156,"tagName":"p"}]},{"val":[{"type":"text","content":"VYD2311 Phase 1 clinical trial data read-out anticipated later in Q2 2025","length":73,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":653,"olType":false},{"type":"text","content":"WALTHAM, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the quarter ended March 31, 2025, and provided recent business highlights.","length":190,"tagName":"p"},{"type":"text","content":"“To drive long-term topline growth, we made a strategic decision to internalize our sales force at the beginning of 2025,” said Bill Duke, Chief Financial Officer of Invivyd. “Although this shift created a short-term headwind, we’re now seeing positive momentum with a return to growth and early signs of acceleration in Q2 2025. Backed by a strong cash position and potential to access up to $30 million in non-dilutive funding through our term loan facility, we remain focused on disciplined financial execution and continue to target profitability...